首页> 外文期刊>Bone marrow transplantation >Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation.
【24h】

Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation.

机译:自体外周血干细胞移植后1年,造血损伤持续存在。

获取原文
获取原文并翻译 | 示例
       

摘要

In the present study we have used cell culture assays in order to assess the damage in the haematopoietic system 1 year after peripheral blood stem cell transplantation (PBSCT), and to establish at what level, haematopoietic progenitor cells (HPC) or stroma, this damage occurs. Thirty-one patients, nine breast cancer (BC), 17 non-Hodgkin lymphoma (NHL) and five Hodgkin disease (HD), who had received autologous PBSCT were included. Forty-eight normal subjects who had given informed consent were used as controls. Results were also compared with a matched group of patients (25 cases) prior to PBSCT. Progenitor cells were analysed using CFU-GM and plastic adherent delta (Pdelta) assays. Long-term bone marrow cultures (LTBMC) in one and two stages were established. One year after transplant both the number of committed progenitor cells and the CFU-GM production in LTBMC were significantly reduced in the three groups of patients when compared with controls (P < 0.05 or P < 0.01). Two-stage LTBMC experiments showed that the impairment in CFU-GM production was due to damage in both patients' stroma and haematopoietic progenitor cells (HPC). All patients, except those with HD, showed a decreased stromal layer confluence (P < 0.05), with significant differences in cell composition as compared to normal bone marrow (P = 0.001). When all these variables were compared with pretransplant results, we observed that stroma formation was significantly lower after PBSCT (P < 0.05), while the number of progenitor cells analysed by the Pdelta assay was significantly increased (P < 0.05). We can conclude that even 1 year after PBSCT, both the committed HPC and BM stroma remain damaged.
机译:在本研究中,我们使用细胞培养测定法来评估外周血干细胞移植(PBSCT)1年后造血系统的损害,并确定造血祖细胞(HPC)或基质处于何种水平发生。接受自体PBSCT治疗的31例患者,9例乳腺癌(BC),17例非霍奇金淋巴瘤(NHL)和5例霍奇金病(HD)。给予知情同意的四十八名正常受试者被用作对照。还将结果与PBSCT之前的一组匹配的患者(25例)进行了比较。祖细胞使用CFU-GM和塑性粘附三角洲(Pdelta)分析进行了分析。建立了一个阶段和两个阶段的长期骨髓培养(LTBMC)。移植后一年,与对照组相比,三组患者的LTMBC中定型祖细胞数量和CFU-GM产量均显着降低(P <0.05或P <0.01)。 LTBMC的两个阶段的实验表明,CFU-GM产生的损伤是由于患者基质和造血祖细胞(HPC)的损伤所致。除患有HD的患者外,所有患者均显示基质层汇合减少(P <0.05),与正常骨髓相比,细胞组成有显着差异(P = 0.001)。当将所有这些变量与移植前的结果进行比较时,我们观察到PBSCT后基质的形成显着降低(P <0.05),而Pdelta分析所分析的祖细胞数量则显着增加(P <0.05)。我们可以得出结论,即使在进行PBSCT的1年后,既定的HPC和BM基质仍然受损。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号